Blvr Valves denied as experimental or investigational by Humana?

Humana's specific coverage criteria for blvr valves are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied BLVR Valves as "Experimental" — and Why That Denial Is Contestable

Endobronchial valves for bronchoscopic lung volume reduction in severe emphysema have received FDA approval (the Zephyr Valve system received FDA De Novo authorization), and professional society guidelines from organizations such as the American Thoracic Society (ATS), European Respiratory Society (ERS), and CHEST address BLVR as an evidence-based option for carefully selected patients. Despite this, some Humana coverage policies continue to classify BLVR valves as investigational or experimental — often because the policy was last updated before the regulatory approval, or because the policy's clinical criteria have not been revised to reflect current guideline consensus.

An "experimental" denial is one of the stronger denial types to appeal precisely because it rests on a coverage determination that can be rebutted with objective evidence: FDA clearance status, published guidelines, and peer-reviewed literature.

## Your Federal Appeal Rights

ACA §2719 requires non-grandfathered plans to provide internal appeal and external review rights. ERISA §503 requires full-and-fair review for employer-sponsored plans. You have up to 180 days to file internally. After an adverse internal decision, you generally have four months to request binding IRO external review. For patients who are clinically deteriorating, request expedited review — a decision within 72 hours is required.

External reviewers at IROs are required to apply generally accepted standards of medical practice and may consider peer-reviewed literature that the plan's own reviewers did not. "Experimental" denials are frequently overturned at external review when FDA approval and guideline endorsement are documented.

## Documentation to Gather

• FDA clearance documentation: Obtain and attach the FDA De Novo authorization or 510(k) clearance letter for the specific valve system being prescribed. This directly rebuts the "not approved" component of an experimental denial.
• Professional society guideline citation: A reference to the current applicable ATS/ERS/CHEST or international emphysema management guideline that addresses BLVR as an evidence-based treatment option for appropriate patients.
• Prescriber medical-necessity letter: A letter from the treating pulmonologist or interventional pulmonologist explaining how the patient meets the eligibility criteria described in the guideline and the FDA-approved indication, citing specific chart findings (without fabricating numbers — reference the chart and the label).
• Peer-reviewed literature summary: Your prescriber can attach a brief summary of the relevant published evidence supporting BLVR in emphysema, referencing the studies' conclusions without the need to cite specific statistics in your appeal letter.
• Humana's experimental/investigational policy: Download Humana's current coverage determination for BLVR valves and address each criterion for "established" status listed there.

## Criteria-Mapping Structure

Build a two-column table: left column quotes each of Humana's criteria for considering a treatment "established" (rather than experimental); right column provides the evidence — FDA letter, guideline name and year, prescriber statement — that satisfies each criterion.